Literature DB >> 26940053

Bone pain: current and future treatments.

Charlotte Ørsted Frost1, Rikke Rie Hansen1, Anne-Marie Heegaard2.   

Abstract

Skeletal conditions are common causes of chronic pain and there is an unmet medical need for improved treatment options. Bone pain is currently managed with disease modifying agents and/or analgesics depending on the condition. Disease modifying agents affect the underlying pathophysiology of the disease and reduce as a secondary effect bone pain. Antiresorptive and anabolic agents, such as bisphosphonates and intermittent parathyroid hormone (1-34), respectively, have proven effective as pain relieving agents. Cathepsin K inhibitors and anti-sclerostin antibodies hold, due to their disease modifying effects, promise of a pain relieving effect. NSAIDs and opioids are widely employed in the treatment of bone pain. However, recent preclinical findings demonstrating a unique neuronal innervation of bone tissue and sprouting of sensory nerve fibers open for new treatment possibilities.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26940053     DOI: 10.1016/j.coph.2016.02.007

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  9 in total

Review 1.  Mechanisms of bone pain: Progress in research from bench to bedside.

Authors:  Gehua Zhen; Yuhan Fu; Chi Zhang; Neil C Ford; Xiaojun Wu; Qichao Wu; Dong Yan; Xueming Chen; Xu Cao; Yun Guan
Journal:  Bone Res       Date:  2022-06-06       Impact factor: 13.362

Review 2.  Mechanisms that drive bone pain across the lifespan.

Authors:  Patrick W Mantyh
Journal:  Br J Clin Pharmacol       Date:  2018-11-22       Impact factor: 4.335

3.  Anti-nerve growth factor does not change physical activity in normal young or aging mice but does increase activity in mice with skeletal pain.

Authors:  Lisa A Majuta; Stefanie A T Mitchell; Michael A Kuskowski; Patrick W Mantyh
Journal:  Pain       Date:  2018-11       Impact factor: 7.926

4.  Decitabine attenuates nociceptive behavior in a murine model of bone cancer pain.

Authors:  Camilla Kristine Appel; Nicole Newell Scheff; Chi Tonglien Viet; Brian Lee Schmidt; Anne-Marie Heegaard
Journal:  Pain       Date:  2019-03       Impact factor: 7.926

5.  The Src family kinase inhibitor dasatinib delays pain-related behaviour and conserves bone in a rat model of cancer-induced bone pain.

Authors:  Camilla Kristine Appel; Simone Gallego-Pedersen; Line Andersen; Sophie Blancheflor Kristensen; Ming Ding; Sarah Falk; Manasi Sayilekshmy; Charlotte Gabel-Jensen; Anne-Marie Heegaard
Journal:  Sci Rep       Date:  2017-07-06       Impact factor: 4.379

6.  Nuclear factor kappa B regulated monocyte chemoattractant protein-1/chemokine CC motif receptor-2 expressing in spinal cord contributes to the maintenance of cancer-induced bone pain in rats.

Authors:  Yungong Wang; Huadong Ni; Hongbo Li; Houshen Deng; Long S Xu; Shijie Xu; Ying Zhen; Hui Shen; Huan Pan; Ming Yao
Journal:  Mol Pain       Date:  2018-06-29       Impact factor: 3.395

7.  B14 ameliorates bone cancer pain through downregulating spinal interleukin-1β via suppressing neuron JAK2/STAT3 pathway.

Authors:  Miao Xu; Huadong Ni; Longsheng Xu; Hui Shen; Housheng Deng; Yungong Wang; Ming Yao
Journal:  Mol Pain       Date:  2019 Jan-Dec       Impact factor: 3.395

8.  Incapacitating pain from Tenofovir Induced Hypophosphatemic Osteomalacia in a Hemophilia Patient - A Case Report.

Authors:  Emma Woo; Dinesh Kumbhare; Paul Winston
Journal:  Can J Pain       Date:  2020-12-14

9.  HIF1α Promotes BMP9-Mediated Osteoblastic Differentiation and Vascularization by Interacting with CBFA1.

Authors:  Yuwan Li; Ziming Liu; Hong-De Wang; Jun Zhang; Miaoyuan Lin; Jianye Yang; Jiaxing Huang; Wenqiang Yan; Yingfang Ao
Journal:  Biomed Res Int       Date:  2022-10-01       Impact factor: 3.246

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.